SGLT-2 inhibitors reduce kidney stone risk by 26% compared to DPP-4 inhibitors
Entered 2024.02.07 19:00 Entered 2024.02.07 19:00 Modified 2024.02.08 14:17 Views 134
A study found that certain types of type 2 diabetes medications significantly lower the risk of developing kidney stones. [사진= 게티이미지뱅크]Patients with type 2 diabetes often develop kidney stones. Kidney stones can cause severe pain and lead to nephritis due to decreased kidney function.
A study found that certain types of type 2 diabetes medications significantly lower the risk of developing kidney stones. This is what the health and medicine portal WebMD reported on the 6th (local time) based on a paper by researchers at Brigham and Women’s Hospital published in the Journal of the American Medical Association (JAMA Internal Medicine).
The researchers hypothesized that sodium-glucose cotransporter-2 (SGLT-2) inhibitors among type 2 diabetes treatments could reduce the risk of kidney stones by changing urine composition. In addition, two types of treatment, an SGLT2 inhibitor and a dipeptidyl peptidase-4 (DPP-4) inhibitor, were prescribed for more than 6 months to approximately 716,000 adult patients with type 2 diabetes in the United States, and the difference in kidney stone risk was evaluated. compared.
They found that patients taking SGLT2 inhibitors had a 26% lower risk of kidney stones compared to patients taking DPP-4 inhibitors. The risk for overall patients taking SGLT2 inhibitors was 31% lower.
It was found that this results in the same results regardless of gender, race, ethnicity, history of chronic kidney disease, or obesity. In particular, it was found that the risk reduction effect was greater in adults under 70 years of age.
“Our findings suggest that the individual risk profile for kidney stones and nephritis may be a consideration when patients with type 2 diabetes decide which glucose-lowering medication to take,” the researchers wrote. Type 2 diabetes treatments that are SGLT-2 inhibitors include bexagliflozin (product name Brenzavi), canagliflozin (Invokana), dapagliflozin (Farxiga), and empagliflozin. (Jadien), etc.
You can check the paper at the following link (
“Copyright ⓒ ‘Honest Knowledge for Health’ Comedy.com ( / Unauthorized reproduction and redistribution, AI learning and use prohibited”
2024-02-08 19:13:47
#diabetes #treatment #lowers #risk #kidney #stones
